- Home
- BKYI vs PLRZ Comparison
BKYI vs PLRZ Comparison
Compare BKYI & PLRZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- PLRZ
- Stock Information
- Founded
- BKYI 1993
- PLRZ 2005
- Country
- BKYI United States
- PLRZ Israel
- Employees
- BKYI N/A
- PLRZ N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- PLRZ
- Sector
- BKYI Technology
- PLRZ
- Exchange
- BKYI Nasdaq
- PLRZ NYSE
- Market Cap
- BKYI 3.5M
- PLRZ 3.4M
- IPO Year
- BKYI 1997
- PLRZ 2024
- Fundamental
- Price
- BKYI $0.92
- PLRZ $3.29
- Analyst Decision
- BKYI
- PLRZ
- Analyst Count
- BKYI 0
- PLRZ 0
- Target Price
- BKYI N/A
- PLRZ N/A
- AVG Volume (30 Days)
- BKYI 119.2K
- PLRZ 7.1M
- Earning Date
- BKYI 11-14-2024
- PLRZ 02-15-2025
- Dividend Yield
- BKYI N/A
- PLRZ N/A
- EPS Growth
- BKYI N/A
- PLRZ N/A
- EPS
- BKYI N/A
- PLRZ N/A
- Revenue
- BKYI $7,292,394.00
- PLRZ N/A
- Revenue This Year
- BKYI $1.96
- PLRZ N/A
- Revenue Next Year
- BKYI $9.65
- PLRZ N/A
- P/E Ratio
- BKYI N/A
- PLRZ N/A
- Revenue Growth
- BKYI N/A
- PLRZ N/A
- 52 Week Low
- BKYI $0.52
- PLRZ $0.77
- 52 Week High
- BKYI $4.12
- PLRZ $4.80
- Technical
- Relative Strength Index (RSI)
- BKYI 41.70
- PLRZ N/A
- Support Level
- BKYI $0.85
- PLRZ N/A
- Resistance Level
- BKYI $1.00
- PLRZ N/A
- Average True Range (ATR)
- BKYI 0.11
- PLRZ 0.00
- MACD
- BKYI -0.02
- PLRZ 0.00
- Stochastic Oscillator
- BKYI 20.00
- PLRZ 0.00
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About PLRZ POLYRIZON LTD
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.